NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer
Novartis (NYSE: NVS) announced that the National Medical Products Administration (NMPA) has approved the radioligand...